MNK Mallinckrodt plc

4.08
-0.01  -0%
Previous Close 4.09
Open 4.1
Price To Book 0.11
Market Cap 342,754,908
Shares 84,008,556
Volume 5,281,742
Short Ratio 14.3
Av. Daily Volume 3,568,638

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 15, 2019 met primary endpoint. NDA filing due early 2020.
Terlipressin
Hepatorenal syndrome (HRS) Type 1
CRL issued August 22, 2018.
Stannsoporfin
Jaundice
Phase 3 enrolment to stop following interim analysis February 20, 2019.
UVADEX (methoxsalen) and Therakos
Acute Graft Versus Host Disease
Phase 2 commencement of enrollment announced August 2, 2018.
MNK-1411
Duchenne Muscular Dystrophy
Approved April 30, 2015.
RAPLIXA
Hemostasis
Phase 3 data due late 2Q or early 3Q 2019.
StrataGraft skin tissue
Deep partial thickness severe burns - skin defects
Phase 2 trial ongoing.
StrataGraft skin tissue
Full thickness severe burns - skin defects
Phase 3 trial did not show a statistically significant separation from placebo.
VTS-270
Niemann-Pick Disease
Phase 3 data due 2H 2020.
Inhaled Xenon Gas Therapy
Post-cardiac arrest
CRL issued December 12, 2018.
MNK-812
Pain
Phase 3 data released May 7, 2019 did not meet primary endpoint.
CPP-1X/sulindac
Familial Adenomatous Polyposis (FAP)
Phase 2 trial discontinued due to safety concerns - July 16, 2019.
H.P. Acthar Gel
Amyotrophic Lateral Sclerosis
Phase 2 commencement of dosing announced August 12, 2019. To be completed 2Q 2020.
MNK-6106
Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)

Latest News

  1. CLASS ACTION UPDATE for LB, EGBN and MNK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  2. Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Mallinckrodt plc – MNK
  3. Are Options Traders Betting on a Big Move in Mallinckrodt (MNK) Stock?
  4. Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Class Action - Bronstein, Gewirtz & Grossman, LLC
  5. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Mallinckrodt plc To Contact The Firm
  6. ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Mallinckrodt plc Investors of Important Deadline in Securities Class Action – MNK
  7. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK
  8. Here's Why Mallinckrodt Dropped 12% Today
  9. Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc
  10. CLASS ACTION UPDATE for MNK, JE, GTT and EVH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  11. Mallinckrodt Confirms Positive Late-Stage Readout For Hepatorenal Syndrome Drug
  12. Mallinckrodt's stock shoots up after positive phase 3 trial data on HRS-1 treatment
  13. Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
  14. Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc
  15. Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC
  16. Is Mallinckrodt (MNK) a Profitable Pick for Value Investors?
  17. SHAREHOLDER DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mallinckrodt plc and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm
  18. Mallinckrodt Announces Publication of Results of Phase 1b Clinical Trial of StrataGraft® Regenerative Tissue in Burns